Heterozygous and homozygous variants in STX1A cause a neurodevelopmental disorder with or without epilepsy
==========================================================================================================

* Johannes Luppe
* Heinrich Sticht
* François Lecoquierre
* Alice Goldenberg
* Kathleen Gorman
* Ben Molloy
* Emanuele Agolini
* Antonio Novelli
* Silvana Briuglia
* Outi Kuismin
* Carlo Marcelis
* Antonio Vitobello
* Anne-Sophie Denommé-Pichon
* Sophie Julia
* Johannes R. Lemke
* Rami Abou Jamra
* Konrad Platzer

## Abstract

The neuronal SNARE complex drive synaptic vesicle exocytosis. Therefore, one of its core proteins syntaxin 1A (STX1A) has long been suspected to play a role in neurodevelopmental disorders. We assembled eight individuals harboring rare variants in *STX1A* who present with a spectrum of intellectual, autism and epilepsy. Causative variants comprise a homozygous splice variant, three *de novo* missense variants and two inframe deletions of a single amino acid. We observed a phenotype mainly driven by epilepsy in the individuals with missense variants in contrast to intellectual disability and autistic behavior in individuals with single amino acid deletions and the splicing variant. *In silico* modeling of missense variants and single amino acid deletions show different impaired protein-protein interactions. We hypothesize the two phenotypic courses of affected individuals to be dependent on two different pathogenic mechanisms: (1) a weakened inhibitory STX1A-STXBP1 interaction due to missense variants results in an *STX1A*-related developmental epileptic encephalopathy and (2) a hampered SNARE complex formation due to inframe deletions causes an *STX1A*-related intellectual disability and autism phenotype.

Key words
*   Epileptic encephalopathy
*   SNAREopathy
*   Synapse

## Introduction

SNARE (soluble NSF attachment protein receptor) complexes play a crucial role in a multitude of membrane fusion processes in the central nervous system. The core complex, comprising neuronal SNAREs syntaxin 1, SNAP25 and VAMP2, mediates synaptic vesicle exocytosis1 as well as secretion of neuropeptides and neurotrophins.2 Syntaxin 1A (encoded by the gene *STX1A*) is localized at the neuronal synaptic plasma membrane. It is involved in regulation of several plasma membrane-bound monoamine transporters.3–6 Variants in *STX1A* have not been shown to cause a mendelian disorder. Of note, *de novo* deletions of *STX1A* was seen in 5 out of 83 individuals with autism spectrum disorder (ASD)7 although a recent analysis of a large ASD cohort did not show a significant association.8 Single nucleotide polymorphisms in *STX1A* are suspected to increase susceptibility to migraine in several case-control-studies9–12 as well as playing a role in predisposition to autism13–15, cryptogenic epilepsy16 and children attention-deficit/hyperactivity disorder17, whereas no associations could be drawn to schizophrenia.18 Due to little redundancy and rescue mechanisms, disruption of components of the SNARE complex give rise to a group of rare diseases called SNAREopathies.19,20 In this study, we describe eight individuals harboring rare homozygous or *de novo* heterozygous variants in *STX1A* to delineate a novel *STX1A*-related neurodevelopmental disorder based on different pathogenic mechanisms and inheritance models.

## Materials (Subjects) and Methods

### Standard protocol approvals

The study was approved by the ethics committee of the University of Leipzig, Germany (402/16-ek). All families provided informed consent for clinical phenotyping, genetic testing and publication. If done in a research setting, testing was approved by local ethics committees in the respective institutions.

### Research cohort and identification of variants

Eight individuals with *STX1A* variants from seven different families were assembled via literature review and GeneMatcher.21 Phenotypic and genotypic information was obtained from the referring collaborators using a standardized questionnaire, evaluating family anamnesis, clinical history, genetic testing, variant details, EEG, brain imaging and medication. All individuals underwent exome or genome sequencing. Since no causative variants in a known disease gene were identified, the data were examined in a scientific approach, including parental sequence data if available. All variants were prioritized considering allele frequency in gnomAD22 below 1%, impact in different *in silico* programs and involvement of candidate genes in neuronal processes. All variants in *STX1A* are described with regard to GRCh37 and NM_004603.3.

### Structural modeling

Structural analysis of the variants was performed based on the crystal structure of Syntaxin 1A in complex with Syntaxin-binding protein 1 (PDB: 3C98)23 or the components of the SNARE complex (PDB: 6IP1, 6MDN).24,25 Amino acid changes were modeled with SwissModel26 and RasMol27 was used for structure analysis and visualization.

## Results

### Clinical description

The eight individuals exhibited varying neurodevelopmental, neurological and neuropsychiatric symptoms. In four out of eight individuals, epilepsy was the leading clinical symptom, whereas in the four remaining individuals intellectual disability and autistic behavior without epilepsy was prominent. An overview of the clinical symptoms is presented in Table 1 and Table S1.

View this table:
[Table 1:](http://medrxiv.org/content/early/2022/04/21/2022.04.20.22274073/T1)

Table 1: 
Summary of clinical symptoms of individuals with rare variants in STX1A

#### Individual 1

This male was first reported in Reuter et al.28 He was born to consangineous parents with normal intelligence. One of his brothers (described below as individual 2) presented with similar symptoms. Another brother had died in infancy (see Figure S1). During pregnancy of individual 1 decreased fetal movements were noted. He was born at term with increased birth length and neonatal hypotonia. He learned unassisted walking at the age of and did not show persistent motor problems in later childhood. Global development and speech were delayed. Clinical assessment at the age of showed moderate intellectual disability with mostly unremarkable speech and behavior. Seizures were denied. MRI or EEG were not performed. No facial dysmorphisms were seen. Most of his time, he worked on the acre of the family.

#### Individual 2

This male was also first reported in Reuter et al.28 and is the younger brother of individual 1. He was born as the in the family described above. As in his brother, decreased fetal movements were noted in pregnancy. After birth at term, neonatal hypotonia and increased birth length were noted. He also learned unassisted walking around age and did not show persistent motor problems in later childhood. Global development and speech were delayed. Clinical assessment at the age of showed moderate intellectual disability, but a mostly unremarkable speech. His behavior was more aggressive compared to his brother. No seizures were recorded. Neither MRI nor EEG were performed. No facial dysmorphisms were seen. As his brother he mostly worked on the acre of the family.

Exome sequencing detected a homozygous variant in *STX1A*:c.284-1G>A in both brothers. The parents and one of the sisters were found to be heterozygous for this variant via Sanger sequencing. Unfortunately, this family was lost to further follow-ups.

#### Individual 3

This male was born after an unremarkable pregnancy to healthy parents. Birth measurements were around the 50th percentile and neonatal hypotonia was observed. This individual was affected by severe global developmental delay. He learned unassisted walking at the age of, but had persistent motor problems in later childhood. Clinically, he was suspected to harbor an Angelman-like disorder. He was able to speak two to three words at the age, but speech was absent at last clinical assessment at the age of . His intellectual disability was assessed to be severe. Abnormal behavior comprised stereotypes, drooling, bruxism, biting and pulling hair and he was diagnosed with ASD. He also had recurrent sleeping problems. Neurological examination showed ptosis, hypotonia, ataxia and spasticity with pyramidal signs. First tonic-clonic seizures were noticed at the age of, reaching a frequency of several per day. A therapy with valproate and levetiracetam was successful to suppress severe seizures for several years, although absences and rare tonic seizures remained. At age of seizures intensified again, reaching frequencies of several tonic and tonic-clonic seizures and absences per day. A switch in medication to rufinamide, valproate and perampanel lead to a limited response with suppressing seizure frequency to one per week. MRIs were normal apart from delayed myelination at three years of age. Family history only elicited a febrile seizure in his maternal uncle at the age of.

Exome sequencing detected a heterozygous *de novo* variant in *STX1A*:c.435C>G, p.(Cys145Trp).

#### Individual 4

A girl, was born after an uneventful pregnancy at 39 weeks of gestation. Birth weight was on the 75th percentile. First seizures occurred on, which was attributed to neonatal hypoglycemia (1.4mmol/L glucose) due to diazoxide responsive congenital hyperinsulinism. She was in the neonatal intensive care unit. After the neonatal period, she was seizure-free until of age, when she presented with febrile seizures, and shortly after recurrent afebrile focal seizures (2-3 per week). Subsequently she developed focal to bilateral tonic-clonic, absence and generalized onset motor tonic-clonic seizures. At age of, she presented with myoclonic, myoclonic absence and focal onset (occipital lobes) seizures. Pharmacological treatment included valproate, phenobarbitone, pyridoxine, levetiracetam, carbamazepine, lamotrigine, zonisamide, clobazam, lacosamide, rufinamide, ethosuximide. Her current seizure frequency is approximately 2 absences and 1 focal seizure per month on sodium valproate and ethosuximide. Age of, weight is on the 50th to 75th percentile. Concerning her cognitive development she started babbling aged but then stopped at indicating a regression of skills. She has severe ID and never acquired speech, but can use picture books to communicate. She walked independently aged, but has persistent motor problems in later childhood with a waddling gait. She has autistic traits but does not meet the criteria for an ASD diagnosis and she was diagnosed with sensory processing disorder. The latest EEG at of age showed a slow background, multifocal epileptiform spikes, and occipital spike waves and generalized irregular-semi-irregular spike waves. MRI performed at of age showed mild periventricular leukoencephalopathy. In family history, the mother had two seizures as a teenager and was treated with Carbamazepine for two years, after which she was weaned. No further seizures occurred.

Trio genome sequencing detected a heterozygous *de novo* variant in *STX1A*: c.435C>G, p.(Cys145Trp).

#### Individual 5

This male was born at term after an unremarkable pregnancy. His birth length was 49 cm (14th percentile), weight 2800 gram (12th percentile) and head circumference 34 cm (17th percentile). Neonatal hypotonia was noticed. He had global developmental delay and persistent motor problems throughout his life, but learnt unassisted walking at the age of. His first speech was noted at the age of. At the age of, his speech was mildly age-inappropriate, reaching 5th centile (Bayley Scales of Infant Development). Moderate intellectual disability as well as behavioral problems such as aggressiveness, hyperactivity, attention deficit and sleeping problems were reported. He had first seizures (loss of consciousness) at the age of with a frequency of one seizure every two to three months. He exhibited right frontal to centero-temporal spikes in EEG and was diagnosed with rolandic epilepsy. Antiepileptic therapy was started at the age of and consisted of Levetiracetam. During therapy, no further seizures occurred, but the EEG anomalies persisted. Neurological examination showed fine intentional tremors as well as global motor impediment. A brain MRI at the age of had normal results. Furthermore, axial hypotonia, a congenital clubfoot and various mild dysmorphisms, including brachycephaly, low set ears, retrognathia, tapered fingers, lower limb muscular hypotrophy and hypotenar eminence as well as hypochromic and coffee-milk skin spots were noted. His weight reached 97th percentile, OFC was at the 36th percentile. In family history, the mother was diagnosed with migraine and a Chiari malformation.

Trio exome sequencing detected a heterozygous *de novo* variant in *STX1A*: c.554C>G, p.(Ser185Cys).

#### Individual 6

This patient had moderate intellectual disability. No seizures were recorded. Unfortunately, this patient was lost to follow-up for further detailed phenotyping. Exome sequencing detected a heterozygous variant in *STX1A*: c.668_670delTGG. p.(Val223del) of unknown origin due to unavailable parental testing.

#### Individual 7

This female was born to healthy parents after 42 weeks of an unremarkable pregnancy. Birth weight was 3300 g, neonatal hypotonia was noted. At the age of, body measurements were: 6085 g (11th percentile), 66 cm (46th percentile) and OFC 41cm (9th percentile). At last follow-up at the age of measurements were: 38 kg (2nd percentile), 150 cm (3rd percentile). She had severe global developmental delay, motor problems (she never learned walking), absence of speech and profound intellectual disability. Neurological examination showed dysphagia, drooling and spastic paresis.

Epileptic spasms became evident at the age of and were associated with hypsarrhythmia on EEG, compatible with West syndrome. Additionally, daily tonic seizures occurred and a severe epileptic encephalopathy developed. Treatment included ACTH, valproate, levetiracetam, clonazepam and cannabidiol, suppressing frequency to weekly intervals but without reaching longer seizure free periods. The encephalopathic phenotype later progressed to Lennox-Gastaut syndrome. A brain MRI at the age of three years showed normal results.

Trio exome sequencing detected a heterozygous *de novo* variant in *STX1A*: c.677A>G, p.(Gln226Arg).

#### Individual 8

This male was born at term to healthy parents after an unremarkable pregnancy. Birth measurements determined a length of 50 cm (8th percentile) and a weight of 3000 g (14th percentile). Neonatal hypotonia was observed. At age of he showed a length of 71 cm (< 1st percentile) and a weight of 9 kg (1st percentile). At of age length was at -3 SD while OFC was at +2 SD. This individual was affected by severe intellectual disability with only few words at last assessment and motor delay with unassisted walking at around four years of age. Behavioral problems compatible with an autism spectrum disorder were noted, including an extreme aggressiveness and sleeping problems. Apart from neonatal hypotonia no further neurological abnormalities could be elicited. The individual had no seizures and brain MRI showed normal results. Additional symptoms included a pes varus and constipation.

Trio exome sequencing showed a heterozygous *de novo* variant in *STX1A*: c.722_724delTAG, p.(Val241del).

### Genotypic spectrum

One homozygous splicing variant, three different *de novo* missense variants and two deletions of a single amino acid (one *de novo*) were observed in *STX1A*. Variants were predicted to be damaging according to multiple *in silico* tools (Tables S2 and S3). The only recurrent variant is the missense variant p.(Cys145Trp) twice occurring *de novo* in individuals with a consistent phenotype.

Furthermore, in the most recent DDD study29, the *de novo* variant c.236T>G, p.(Met79Arg) was reported in an individual with a neurodevelopmental disorder, but a detailed phenotypic description is not available.

### Structural modeling

All residues affected by a variant in the present study are resolved in the crystal structure of STX1A in complex with syntaxin-binding protein 1 (STXBP1).23 In this complex, residues 29-237 of STX1A form a rather compact structure comprising four helices (Fig. 2A). This conformation was termed ‘closed’ conformation in the literature.23 The major effect of the missense variants are steric clashes, which destabilize the STX1A structure and are therefore expected to hamper interaction with STXBP1. A similar negative effect is expected for the deletion of p.(Val223del), which disrupts the helical structure of the H3 domain (residues 186-253). In contrast, p.(Val241del) plays only a minor role for binding to STXBP1. An experimental investigation proved that deletion of syntaxin1A residues 241-262 caused only a very moderate decrease in STXBP1 affinity by a factor of two23.

![Fig. 1:](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2022/04/21/2022.04.20.22274073/F1.medium.gif)

[Fig. 1:](http://medrxiv.org/content/early/2022/04/21/2022.04.20.22274073/F1)

Fig. 1: Overview of variants in *STX1A*
(a) Schematic depiction of STX1A. Segments of particular functional importance are displayed colored and named. The lollipop bars indicate observed causative variants of this study

(b) Association of observed variants with a tolerance landscape of STX1A created by Metadome42. Height and color of the graph indicate tolerance towards variation in the referring amino acid residues: the lower and redder the bar, the less tolerant to variation is the specific residue.

(c) Comparison of selected homologous amino acid residues of STX1A and STX1B. Colored positions mark residues with causative/pathogenic variants in the referring protein.

![Fig. 2:](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2022/04/21/2022.04.20.22274073/F2.medium.gif)

[Fig. 2:](http://medrxiv.org/content/early/2022/04/21/2022.04.20.22274073/F2)

Fig. 2: Structure of STX1A in complex with different binding partners.
(a) Structure of STX1A in complex with STXBP1 (PDB: 3C98). STXBP1 and STX1A are colored in red and cyan/blue, respectively, with the H3 domain of STX1A highlighted in blue. The residues at the sites of mutation are shown in space-filled presentation and colored according to the atom types.

(b) Structure of STX1A as part of the SNARE complex (PDB: 6IP1). STX1A, vesicle-associated membrane protein 2, SNAP25, and α-SNAP are colored in blue, orange, green, and white, respectively. The residues at the sites of mutation are shown in space-filled presentation and colored according to the atom types. Note that only three of the variants investigated are locate in the SNARE-interacting region.

For a structural interpretation of variant effects, it is important to note that STX1A can also adopt a structurally distinct ‘open’ conformation as part of the SNARE complex. In this complex, the H3 domain forms a long central helix that interacts with the other components of the SNARE complex (Fig. 2B). Both deletion variants p.(Val223del), p.(Val241del) are located in the central part of this helix. One-residue deletions at these sites significantly affect the helix structure and are expected to hamper SNARE complex formation. The effect of the p.(Gln226Arg) variant is known from experiment; site-directed mutagenesis revealed that this exchange results a significantly slower dissociation of the SNARE complex30.

## Discussion

In this study, we delineate a novel *STX1A*-related neurodevelopmental disorder based on different pathogenic mechanisms and inheritance models.

Given the data from the gnomAD database, *STX1A* is a gene with a reduced number of missense (z score = 2.4, observed/expected ratio = 0.51 (0.43 - 0.61)) and truncating/splice variants (pLI score = 0.98 observed/expected ratio = 0.06 (0.02 - 0.29)). This indicates a selective constraint on those types of variants in a healthy control population that lacks severe early onset phenotypes such as intellectual disability.22 All variants of this study are absent from the GnomAD database and all except the inherited splicing and the p.(Val223del) variant of unknown origin were *de novo*. Moreover, the causality of the variants is supported by strong *in silico* data31,32 and the structural modeling performed in this study.

In all individuals with rare variants in *STX1A*, intellectual disability, neonatal hypotonia and motor delay were present. It appears as if two different phenotypic courses are existing, following the dichotomy of the identified variants and structural modeling: (1) an epileptic encephalopathy in all individuals with missense variants and (2) a neurodevelopmental disorder with primarily intellectual disability and autistic behavior, but no epilepsy in the individuals with an inframe deletion or the family with the homozygous splice variant. The latter resembles the clinical presentation of *STX1A* haploid individuals in a Japanese ASD cohort7 where the probands exhibited normal or only mildly impaired intelligence with no epilepsy, but no deep phenotyping was performed. Epilepsy is also rare in individuals with Williams-Beuren-Syndrome33, who often lack one allele of *STX1A*, and in whom differences in transcript levels of *STX1A* have been shown to account for 15.6% of cognitive variation.34,35 In addition, one individual with a high quality heterozygous canonical splice site variant is listed in GnomAD_v2 and v3 respectively and therefore unlikely to be affected by intellectual disability. Thus, it appears likely that monoallelic loss of *STX1A* leads to varying defects of cognition and social behavior without severe early onset symptoms. This could explain the recessive inheritance mode in family 1 and why severe symptoms became evident in the two homozygous individuals. Epilepsy only occurs in individuals with missense variants in *STX1A* that are predicted to disturb the interaction of STX1A with STXBP1. Since both loss and gain of function variants in STXBP1 are a known cause of a developmental and epileptic encephalopathy36, it is tempting to speculate that the phenotypic differences in *STX1A* are also a result of loss- and gain-of-function effects in protein function. This will have to be examined in follow-up functional studies of the causative variants.

In established SNAREopathies, the most common symptoms comprise neurodevelopmental delay in domains of speech, language, motor function and intellectual ability. Additionally, other neurological symptoms such as seizures, spasms and ataxia as well as social behavioural abnormalities are observed. Severity and frequency of specific symptoms vary depending on the affected gene.19 The phenotype of the probands in the presented cohort in *STX1A* is therefore compatible with known SNARE-associated disorders caused by variants in *SNAP25, VAMP2, STX1B* and *STXBP1*.

Comparison of STX1A and the closely related STX1B is of special importance. The proteins show identical amino acids at more than 82 percent of positions.37 Mostly truncating, but also several missense variants in *STX1B* are known to cause a childhood epilepsy syndrome with both febrile and afebrile seizures, typically with a benign course and good response to treatment. Intelligence is usually normal, although more severely affected individuals have been described.38 Interestingly, missense variants are described to cause a more severe phenotype than null variants.39 For two of *STX1A* missense variants described in the present cohort, pathogenic variation in corresponding *STX1B* residues are described: In case of the *STX1A* variant p.(Cys145Trp), a missense variant affecting the homologous residue in *STX1B*: p.(Cys144Phe) was previously described as likely pathogenic.39 Interestingly, this individual showed additional features such as tremor and cerebellar ataxia that are not typical symptoms of *STX1B*-related generalized epilepsy with febrile seizures. For the *STX1A* variant p.(Gln226Arg) in an individual with West syndrome and Lennox-Gastaut syndrome, the homologous residue directly adjacent is affected in *STX1B*: p.(Gly226Arg) by a *de novo* variant in an individual with yet another developmental and epileptic encephalopathy with myoclonic-atonic epilepsy.38

Attempts to examine clinical relevance via stx1a ablated mice (null and heterozygous deletion) showed atypical social behavior and abnormal recognition profiles in a dose dependent manner.7,40,41 The observation of autistic symptoms in mice is another line of evidence that non-functional *STX1A*-variants rather cause a phenotype of autism and intellectual disability in humans.

STX1A adopts at least two distinct conformations; a ‘closed’ inhibitory conformation in complex with STXBP1 (Fig. 2A) and an ‘open’ conformation in the SNARE complex (Fig. 2B). In particular, the H3 domain (residues 186-253) forms entirely different interactions in both complexes. When bound to STXBP1, the H3 domain interacts with the N-terminal part of STX1A, rendering it inaccessible to its partner molecules in the SNARE complex. Therefore, incorporation of STX1A into a SNARE complex requires dissociation from STXBP1 and switch to an open conformation, in which the H3 domain is accessible.23 Consequently, variants may either affect the STX1A-STXBP1 complex and/or formation of the SNARE complex. Based on the structural modelling, all variants except p.(Val241del) cause a destabilization of the STX1A-STXBP1 complex thereby shifting the conformational equilibrium towards the open STX1A conformation. A reduced ability to form a functional SNARE complex is expected for the inframe deletions p.(Val223del) and p.(Val241del). In contrast, the missense variant p.(Gln226Arg) stabilizes this complex by causing a slower dissociation.30 These different effects on SNARE complex functioning (stabilization vs. destabilization) also offer an explanation for the different phenotype of p.(Gln226Arg) compared to the individuals harboring a deletion.

In the light of the considerations above, the phenotype of intellectual disability with epilepsy is most likely correlated with variants that weaken the inhibitory STX1A-STXBP1 interaction and do not disrupt STX1A function in SNARE complex formation. In contrast, the deletion variants, which mainly hamper SNARE complex formation, result in a different phenotype of intellectual disability and autism without seizures.

## Conclusion

In summary, different lines of evidence presented here support that rare heterozygous and homozygous variants in *STX1A* cause a neurodevelopmental disorder with two different phenotypic presentations: (1) an *STX1A*-related developmental epileptic encephalopathy due missense variants weakening the inhibitory STX1A-STXBP1 interaction and (2) an *STX1A*-related intellectual disability and autism phenotype due inframe deletions hampering SNARE complex formation. Our description thus expands the group of disorders called SNAREopathies.

## Supporting information

Supplemental Data [[supplements/274073_file04.docx]](pending:yes)

## Data Availability

All data produced in the present study are available upon reasonable request to the authors.

## Author Contributions

Conceptualization: R.A.J, K.P. Investigation: J.L, K.P.; Structural modeling: H.S.; Clinical data and genetic analysis: R.A.J., F.L., A.G., K.G., E.A., S.B., O.K., C.M., A.V., A.-S.D.-P., S.J. Visualization: H.S., J.L. Writing—original draft preparation: J.L., K.P., H.S. Review and editing of manuscript: all authors.

## Funding

F.L. and A.G. received funding from European Union and Région Normandie in the context of Recherche Innovation Normandie (RIN 2018). Europe gets involved in Normandie with the European Regional Development Fund (ERDF).

## Ethical Approval

The study was approved by the ethics committee of the University of Leipzig, Germany (402/16-ek).

## Competing Interests

The authors declare that no conflict of interest exists.

## Supplementary material

Supplemental data are in two separate files: a .pdf-file containing Figure S1, Table S2 and Table S3. Table S1 is provided as an excel-file.

## Acknowledgement

We thank the families for their participation and support of this study.

## Footnotes

*   **Disclaimer:** due to medRxiv policy, all information has been removed that would allow the patient / study participant or their family, friends or neighbors to identify them (e.g., age, precise location, date of hospital admission, family relationships, past medical history, etc).

## Abbreviations

DD/ID
:   developmental delay/intellectual disability
ASD
:   autism spectrum disorder
OFC
:   occipitofrontal circumference

*   Received April 20, 2022.
*   Revision received April 20, 2022.
*   Accepted April 21, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at [http://creativecommons.org/licenses/by-nd/4.0/](http://creativecommons.org/licenses/by-nd/4.0/)

## References

1.  1.Südhof TC, Rothman JE. Membrane Fusion: Grappling with SNARE and SM Proteins. Science. 2009;323(5913):474–477. doi:10.1126/science.1161748
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjEyOiIzMjMvNTkxMy80NzQiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wNC8yMS8yMDIyLjA0LjIwLjIyMjc0MDczLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

2.  2.Arora S, Saarloos I, Kooistra R, van de Bospoort R, Verhage M, Toonen RF. SNAP-25 gene family members differentially support secretory vesicle fusion. J Cell Sci. 2017;130(11):1877–1889. doi:10.1242/jcs.201889
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NToiam9jZXMiO3M6NToicmVzaWQiO3M6MTE6IjEzMC8xMS8xODc3IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDQvMjEvMjAyMi4wNC4yMC4yMjI3NDA3My5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

3.  3.Sung U, Apparsundaram S, Galli A, et al. A Regulated Interaction of Syntaxin 1A with the Antidepressant-Sensitive Norepinephrine Transporter Establishes Catecholamine Clearance Capacity. J Neurosci. 2003;23(5):1697–1709. doi:10.1523/JNEUROSCI.23-05-01697.2003
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Njoiam5ldXJvIjtzOjU6InJlc2lkIjtzOjk6IjIzLzUvMTY5NyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA0LzIxLzIwMjIuMDQuMjAuMjIyNzQwNzMuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

4.  4.Quick MW. Regulating the Conducting States of a Mammalian Serotonin Transporter. Neuron. 2003;40(3):537–549. doi:10.1016/S0896-6273(03)00605-6
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0896-6273(03)00605-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=14642278&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000186379000013&link_type=ISI) 

5.  5.1.  Sitte HH, 
    2.  Freissmuth M
    
    Quick MW. The Role of SNARE Proteins in Trafficking and Function of Neurotransmitter Transporters. In: Sitte HH, Freissmuth M, eds. Neurotransmitter Transporters. Handbook of Experimental Pharmacology. Springer; 2006:181–196. doi:10.1007/3-540-29784-7_9
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/3-540-29784-7_9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16722236&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

6.  6.Carvelli L, Blakely RD, DeFelice LJ. Dopamine transporter/syntaxin 1A interactions regulate transporter channel activity and dopaminergic synaptic transmission. PNAS. 2008;105(37):14192–14197. doi:10.1073/pnas.0802214105
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMjoiMTA1LzM3LzE0MTkyIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDQvMjEvMjAyMi4wNC4yMC4yMjI3NDA3My5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

7.  7.Kofuji T, Hayashi Y, Fujiwara T, Sanada M, Tamaru M, Akagawa K. A part of patients with autism spectrum disorder has haploidy of HPC-1/syntaxin1A gene that possibly causes behavioral disturbance as in experimentally gene ablated mice. Neuroscience Letters. 2017;644:5–9. doi:10.1016/j.neulet.2017.02.052
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neulet.2017.02.052&link_type=DOI) 

8.  8.Fu JM, Satterstrom FK, Peng M, et al. Rare Coding Variation Illuminates the Allelic Architecture, Risk Genes, Cellular Expression Patterns, and Phenotypic Context of Autism. medRxiv; 2021. doi:10.1101/2021.12.20.21267194
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyMS4xMi4yMC4yMTI2NzE5NHYxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDQvMjEvMjAyMi4wNC4yMC4yMjI3NDA3My5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

9.  9.Lemos C, Pereira-Monteiro J, Mendonça D, et al. Evidence of Syntaxin 1A Involvement in Migraine Susceptibility: A Portuguese Study. Arch Neurol. 2010;67(4). doi:10.1001/archneurol.2010.37
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/archneurol.2010.37&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20385907&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000276559500008&link_type=ISI) 

10. 10.Kowalska M, Prendecki M, Kapelusiak-Pielok M, et al. Analysis of Genetic Variants in SCN1A, SCN2A, KCNK18, TRPA1 and STX1A as a Possible Marker of Migraine. CG. 2020;21(3):224–236. doi:10.2174/1389202921666200415181222
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2174/1389202921666200415181222&link_type=DOI) 

11. 11.Tropeano M, Wöber-Bingöl C, Karwautz A, et al. Association analysis of STX1A gene variants in common forms of migraine. Cephalalgia. 2012;32(3):203–212. doi:10.1177/0333102411433300
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/0333102411433300&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22250207&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000300189800005&link_type=ISI) 

12. 12.Corominas R, Ribasés M, Cuenca-León E, et al. Contribution of syntaxin 1A to the genetic susceptibility to migraine: a case-control association study in the Spanish population. Neurosci Lett. 2009;455(2):105–109. doi:10.1016/j.neulet.2009.03.011
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neulet.2009.03.011&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19368856&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000265622100007&link_type=ISI) 

13. 13.Nakamura K, Anitha A, Yamada K, et al. Genetic and expression analyses reveal elevated expression of syntaxin 1A (STX1A) in high functioning autism. Int J Neuropsychopharmacol. 2008;11(8):1073–1084. doi:10.1017/S1461145708009036
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1017/S1461145708009036&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18593506&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000261112100005&link_type=ISI) 

14. 14.Nakamura K, Iwata Y, Anitha A, et al. Replication study of Japanese cohorts supports the role of STX1A in autism susceptibility. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):454–458. doi:10.1016/j.pnpbp.2010.11.033
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.pnpbp.2010.11.033&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21118708&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

15. 15.Durdiaková J, Warrier V, Banerjee-Basu S, Baron-Cohen S, Chakrabarti B. STX1A and Asperger syndrome: a replication study. Mol Autism. 2014;5(1):14. doi:10.1186/2040-23925-14
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/2040-2392-5-14&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24548729&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

16. 16.Baghel R, Grover S, Kaur H, et al. Synergistic association of STX1A and VAMP2 with cryptogenic epilepsy in North Indian population. Brain Behav. 2016;6(7):e00490. doi:10.1002/brb3.490
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/brb3.490&link_type=DOI) 

17. 17.Wang M, Gu X, Huang X, Zhang Q, Chen X, Wu J. STX1A gene variations contribute to the susceptibility of children attention-deficit/hyperactivity disorder: a case–control association study. Eur Arch Psychiatry Clin Neurosci. 2019;269(6):689–699. doi:10.1007/s00406-019-01010-3
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00406-019-01010-3&link_type=DOI) 

18. 18.Kawashima K, Kishi T, Ikeda M, et al. No association between tagging SNPs of SNARE complex genes (STX1A, VAMP2 and SNAP25) and schizophrenia in a Japanese population. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(7):1327–1331. doi:10.1002/ajmg.b.30781
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/ajmg.b.30781&link_type=DOI) 

19. 19.Verhage M, Sørensen JB. SNAREopathies: Diversity in Mechanisms and Symptoms. Neuron. 2020;107(1):22–37. doi:10.1016/j.neuron.2020.05.036
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neuron.2020.05.036&link_type=DOI) 

20. 20.Klöckner C, Sticht H, Zacher P, et al. Correction to: De novo variants in SNAP25 cause an early-onset developmental and epileptic encephalopathy. Genet Med. 2021;23(4):796. doi:10.1038/s41436-020-01090-w
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41436-020-01090-w&link_type=DOI) 

21. 21.Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36(10):928–930. doi:10.1002/humu.22844
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/humu.22844&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26220891&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

22. 22.Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–443. doi:10.1038/s41586-020-2308-7
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-020-2308-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32461654&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

23. 23.Burkhardt P, Hattendorf DA, Weis WI, Fasshauer D. Munc18a controls SNARE assembly through its interaction with the syntaxin N-peptide. EMBO J. 2008;27(7):923–933. doi:10.1038/emboj.2008.37
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiZW1ib2pubCI7czo1OiJyZXNpZCI7czo4OiIyNy83LzkyMyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA0LzIxLzIwMjIuMDQuMjAuMjIyNzQwNzMuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

24. 24.Huang X, Sun S, Wang X, et al. Mechanistic insights into the SNARE complex disassembly. Sci Adv. 2019;5(4):eaau8164. doi:10.1126/sciadv.aau8164
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo4OiJhZHZhbmNlcyI7czo1OiJyZXNpZCI7czoxMjoiNS80L2VhYXU4MTY0IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDQvMjEvMjAyMi4wNC4yMC4yMjI3NDA3My5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

25. 25.White KI, Zhao M, Choi UB, Pfuetzner RA, Brunger AT. Structural principles of SNARE complex recognition by the AAA+ protein NSF. Elife. 2018;7:e38888. doi:10.7554/eLife.38888
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7554/eLife.38888&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30198481&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

26. 26.Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997;18(15):2714–2723. doi:10.1002/elps.1150181505
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/elps.1150181505&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=9504803&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000071948300004&link_type=ISI) 

27. 27.Sayle RA, Milner-White EJ. RASMOL: biomolecular graphics for all. Trends Biochem Sci. 1995;20(9):374. doi:10.1016/s0968-0004(00)89080-5
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0968-0004(00)89080-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=7482707&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1995RU81400014&link_type=ISI) 

28. 28.Reuter MS, Tawamie H, Buchert R, et al. Diagnostic Yield and Novel Candidate Genes by Exome Sequencing in 152 Consanguineous Families With Neurodevelopmental Disorders. JAMA Psychiatry. 2017;74(3):293–299. doi:10.1001/jamapsychiatry.2016.3798
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamapsychiatry.2016.3798&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28097321&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

29. 29.Kaplanis J, Samocha KE, Wiel L, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature. 2020;586(7831):757–762. doi:10.1038/s41586-020-2832-5
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-020-2832-5&link_type=DOI) 

30. 30.Scales SJ, Yoo BY, Scheller RH. The ionic layer is required for efficient dissociation of the SNARE complex by α-SNAP and NSF. PNAS. 2001;98(25):14262–14267. doi:10.1073/pnas.251547598
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMToiOTgvMjUvMTQyNjIiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wNC8yMS8yMDIyLjA0LjIwLjIyMjc0MDczLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

31. 31.Rentzsch P, Schubach M, Shendure J, Kircher M. CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores. Genome Medicine. 2021;13(1):31. doi:10.1186/s13073-021-00835-9
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s13073-021-00835-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33618777&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

32. 32.Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet. 2016;99(4):877–885. doi:10.1016/j.ajhg.2016.08.016
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ajhg.2016.08.016&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27666373&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

33. 33.Nicita F, Garone G, Spalice A, et al. Epilepsy is a possible feature in Williams-Beuren syndrome patients harboring typical deletions of the 7q11.23 critical region. Am J Med Genet A. 2016;170A(1):148–155. doi:10.1002/ajmg.a.37410
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/ajmg.a.37410&link_type=DOI) 

34. 34.Gao MC, Bellugi U, Dai L, et al. Intelligence in Williams Syndrome is related to STX1A, which encodes a component of the presynaptic SNARE complex. PLoS One. 2010;5(4):e10292. doi:10.1371/journal.pone.0010292
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0010292&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20422020&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

35. 35.Botta A, Novelli G, Mari A, et al. Detection of an atypical 7q11.23 deletion in Williams syndrome patients which does not include the STX1A and FZD3 genes. J Med Genet. 1999;36(6):478–480.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToiam1lZGdlbmV0IjtzOjU6InJlc2lkIjtzOjg6IjM2LzYvNDc4IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDQvMjEvMjAyMi4wNC4yMC4yMjI3NDA3My5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

36. 36.Lammertse HCA, van Berkel AA, Iacomino M, et al. Homozygous STXBP1 variant causes encephalopathy and gain-of-function in synaptic transmission. Brain. 2020;143(2):441–451. doi:10.1093/brain/awz391
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/brain/awz391&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31855252&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

37. 37.Align results [completed]. Accessed August 21, 2021. [https://www.uniprot.org/align/A202108214ABAA9BC7178C81CEBC9459510EDDEA30054912](https://www.uniprot.org/align/A202108214ABAA9BC7178C81CEBC9459510EDDEA30054912)
    
    

38. 38.Schubert J, Siekierska A, Langlois M, et al. Mutations in STX1B, encoding a presynaptic protein, cause fever-associated epilepsy syndromes. Nat Genet. 2014;46(12):1327–1332. doi:10.1038/ng.3130
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ng.3130&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25362483&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

39. 39.Wolking S, May P, Mei D, et al. Clinical spectrum of STX1B-related epileptic disorders. Neurology. 2019;92(11):e1238–e1249. doi:10.1212/WNL.0000000000007089
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1212/WNL.0000000000007089&link_type=DOI) 

40. 40.Fujiwara T, Snada M, Kofuji T, Yoshikawa T, Akagawa K. HPC-1/syntaxin 1A gene knockout mice show abnormal behavior possibly related to a disruption in 5-HTergic systems. European Journal of Neuroscience. 2010;32(1):99–107. doi:10.1111/j.1460-9568.2010.07269.x
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1460-9568.2010.07269.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20576034&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom) 

41. 41.Fujiwara T, Kofuji T, Akagawa K. Disturbance of the reciprocal-interaction between the OXTergic and DAergic systems in the CNS causes atypical social behavior in syntaxin 1A knockout mice. Behavioural Brain Research. 2021;413:113447. doi:10.1016/j.bbr.2021.113447
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.bbr.2021.113447&link_type=DOI) 

42. 42.Wiel L, Baakman C, Gilissen D, Veltman JA, Vriend G, Gilissen C. MetaDome: Pathogenicity analysis of genetic variants through aggregation of homologous human protein domains. Hum Mutat. 2019;40(8):1030–1038. doi:10.1002/humu.23798
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/humu.23798&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31116477&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F21%2F2022.04.20.22274073.atom)